BMS-986165 was recently reported as an effective therapeutic for psoriasis in phase II trials (54), and has been shown to inhibit the pseudokinase domain of TYK2 to provide a therapeutic effect against type I IFN– and IL-12–dependent autoimmune disease models in vivo (55). Here, TYK2 is linked to autoimmune disease.